about
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomasA systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcomaSynergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcomaExomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomasAn observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomasMyxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.Advances in the targeted therapy of liposarcoma.Retroperitoneal liposarcoma: current insights in diagnosis and treatmentWhole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements.Aberrant AKT activation drives well-differentiated liposarcomaWell-differentiated abdominal liposarcoma: experience of a tertiary care centerRecurrent retroperitoneal liposarcoma in a patient with neurofibromatosis type I.NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcomaCharacterization of liposarcoma cell lines for preclinical and biological studies.Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcomaSAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewalOverexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival.Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case reportProgression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin.Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.Application of high-resolution genomic profiling in the differential diagnosis of liposarcoma.¹⁸F-FDG-PET/CT findings of retroperitoneal tumors: a pictorial essay.Retroperitoneal sarcomas: a review of disease spectrum, radiological features, characterisation and management.Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial resultsSurgical management of spinal liposarcoma: a case series of 7 patients and literature review.Peritoneal sarcomatosis: site of origin for the establishment of an in vitro and in vivo cell line model to study therapeutic resistance in dedifferentiated liposarcoma.SRC inhibition represents a potential therapeutic strategy in liposarcoma.HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.Recent translational research into targeted therapy for liposarcoma.Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas.Mediastinal liposarcoma in a 30-year-old woman with dyspnea and chest pain.p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma.Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
P2860
Q28076210-8BB56CCB-2A07-41D2-9D22-F928FB1A1CC3Q28482357-79F304B6-AF9E-427D-B981-9505ECF25CE3Q28541805-9E29E0E5-C7D6-4A35-83E2-2ADAFC8C6E85Q33554186-3739F0B5-9961-411A-910F-BDB85A740998Q33640890-714850AD-4A93-4B39-B648-502DF70B3FC8Q34263394-00A2E1AF-B435-4DB3-8FBC-D9783C7205ABQ34952133-A655F669-D9ED-4581-865A-234FFC06B573Q35066363-049073CE-8A46-446F-9A63-1A46C2D4C44BQ35088118-F86FDF58-AB28-49E5-8C29-805BFB5BB758Q35239698-7C4B945E-83B4-4616-9FF4-4F145378BB20Q35575769-6AED77F6-4300-4D3A-A0B9-5F54C8D66F11Q35976727-E206F003-DA42-45E8-8323-CF4D37E49379Q35992165-E16D22B4-FF89-41F9-B5D6-A342C947E2F8Q36111589-24274DBC-1285-4E04-973D-825D6193D74FQ36288319-6B6E73DA-C9AE-438F-82B1-473AD7917A2BQ36642763-BA15A418-0826-47DA-9673-7540416E719EQ36762656-74670CB4-6220-4A3B-B5FC-7AF31CB5CE07Q36898111-69B63C39-2DDB-4BCE-8D78-9C7DF1061B34Q37082518-B6377F47-051D-4B74-93BB-6569189EDC26Q37164989-D7E7206A-20BE-44D9-8CF1-754AE2FCB73BQ37189243-2A42B0EF-5E08-4E37-A8B1-D2DFBBB63C54Q37388663-D0E60EAB-5A9C-40BB-BD2A-9BB60AF84255Q37644536-BA2081B7-F5AF-4E68-B644-9548118A0AEFQ37687307-28725A8F-8190-4184-B31C-B3ACC95D4B4AQ37688106-90D52A59-E9A7-4190-97A6-224B13EAD95DQ37702556-216141C4-6201-48F3-898A-D644425C9231Q37708312-1BCC070A-A747-4978-B491-B41678593684Q38086122-18255186-E6F1-460D-BAE4-050DD6FBA8E0Q38151951-1EDDA2D3-C906-45D9-A502-2899E2654736Q38161734-F8AEE662-102C-4235-922E-13153C2AD4D8Q38701921-C5D26DD5-BA0A-4E13-B37E-DEF9B4732433Q38835065-3A285C4E-9CD3-4F0B-80D9-59EC23C87AB6Q38862860-3136BF4A-AE95-40B3-BE05-54647C4A3274Q38885415-ACA931F4-6EFE-434D-9287-C2BE4B2829C7Q38927569-A9717024-7977-4D70-89DE-EFB54BF16A63Q39265801-6F5B3C39-28F0-490F-B550-A37A015F7B88Q41764961-4CEDCE32-9DED-4B25-AB7C-AA6B399210F9Q41892033-B7B6BC38-D63A-40DE-BB70-527FBABE1F1AQ45781889-E917918D-E897-460F-A95D-F184DCF6FFF0Q46688699-1D7CC2DC-2817-429A-88FC-F604ADDBE082
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Liposarcoma: molecular genetics and therapeutics.
@en
Liposarcoma: molecular genetics and therapeutics.
@nl
type
label
Liposarcoma: molecular genetics and therapeutics.
@en
Liposarcoma: molecular genetics and therapeutics.
@nl
prefLabel
Liposarcoma: molecular genetics and therapeutics.
@en
Liposarcoma: molecular genetics and therapeutics.
@nl
P2860
P356
P1433
P1476
Liposarcoma: molecular genetics and therapeutics
@en
P2093
Rachel Conyers
Sophie Young
P2860
P304
P356
10.1155/2011/483154
P577
2010-12-27T00:00:00Z